Clinical Researchers

Jamie Walker, MD, PhD

Studies focus on dementia and successful aging. “Successful agers” are resistant or resilient to the Alzheimer-type neuropathologic changes that develop in many people as they age. Understanding the process of resistance or resilience to these neuropathologic changes in successful agers will bring insight into mechanisms of prevention and ideally lead o the development of therapeutic interventions for dementia.

Hector Treviño, MPH

Hector Treviño manages epidemiologic research studies in Alzheimer’s disease that identify genetic, environmental, social-behavioral, vascular and metabolic factors and their pathways to dementia pathogenesis using observational study designs and innovative analytic techniques from biostatistics and computational biology. He also manages a double-blind, randomized controlled trial that aims to evaluate the efficacy and safety of DBS-f stimulation to slow the cognitive and functional progression of Alzheimer’s disease.

A. Campbell Sullivan, PSYD, ABPP-CN

Sudha Seshadri, MD

Dr. Seshadri is a senior investigator of the Framingham Heart Study since 1998, leading the study’s clinical neurology and neurogenesis cores since 2005. She is the principal investigator on 8 NIH funded grants and is an investigator, subcontract principal investigator and consultant to 12 additional grants.

She has served on the Editorial Board for Neurology and Stroke, chaired a standing NIH Study Section (Neurology, Aging and Musculoskeletal Epidemiology) and has over 320 peer-reviewed publications (H-index 79, i10 index 209), including 57 in 2016.

Dr. Seshadri helped to establish the neurology phenotype working group within the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium.

She lectures extensively, nationally and internationally, on Alzheimer’s disease, dementia and the genetics of stroke and vascular brain injury.